Omega Fund Management, LLC
In its 13F for Q2 2024 (holdings as of June 30, 2024, filed August 14, 2024), Omega Fund Management, LLC reported 11 stock positions worth $135.0 million. Its top holding was Nuvation Bio (NUVB) at 28.7% of the portfolio, followed by Lexeo Therapeutics (LXEO, 28.0%) and Replimune (REPL, 16.4%). Compared with Q1 2024, it opened 1 new position, sold out of 1 and reduced 3. The biggest buy was a new position in Alumis (ALMS) and the biggest sale Nuvation Bio (NUVB, shares −6%).
- Most Recent 13F
- Q2 2026
- Location
- Boston, MA
- CIK
- 0001637359
- Portfolio Value
- $135.0M (Q2 2024)
- SEC Filing
- 0000950123-24-008730 ↗ filed Aug 14, 2024
Holdings Value
Holdings 11 stocks · $135.0M
| NUVB Nuvation Bio Inc. | 28.72% | 13,275,884 | $38.8M | Reduce -5.7% |
| LXEO Lexeo Therapeutics Inc. | 28.00% | 2,355,904 | $37.8M | No change |
| REPL Replimune Group Inc. | 16.41% | 2,461,319 | $22.2M | Reduce -18.0% |
| ENGN Engene Holdings Inc. | 7.52% | 1,076,357 | $10.2M | No change |
| ALMS Alumis Inc. | 6.44% | 653,225 | $8.7M | New |
| MORF Morphic Holding Inc. | 4.03% | 159,846 | $5.4M | No change |
| SANA Sana Biotechnology Inc. | 3.41% | 843,750 | $4.6M | No change |
| IKENA ONCOLOGY INC | 2.75% | 2,249,123 | $3.7M | No change |
| IMUX Immunic Inc. | 1.47% | 1,788,160 | $2.0M | No change |
| SYRS Syros Pharmaceuticals Inc. | 0.96% | 251,270 | $1.3M | No change |
| ENGENE HOLDINGS INC | 0.28% | 321,502 | $383K | Reduce -10.9% |
Portfolio Sells Q1 2024 → Q2 2024
| NUVB Nuvation Bio Inc. | Reduce -5.7% | 28.72% | −4.32 |
| ENGENE HOLDINGS INC | Reduce -10.9% | 0.28% | −0.93 |
| KRON Kronos Bio Inc. | Sold out | 0.00% | −0.80 |
| REPL Replimune Group Inc. | Reduce -18.0% | 16.41% | +0.59 |
Portfolio Buys Q1 2024 → Q2 2024
| ALMS Alumis Inc. | New | 6.44% | +6.44 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 10 | $185.7M | BCAX, NUVB, KMTS, BBOT, BBNX |
| Q1 2026 | 10 | $163.1M | BCAX, NUVB, BBOT, KMTS, BBNX |
| Q4 2025 | 11 | $286.5M | NUVB, BBOT, BBNX, BCAX, KMTS |
| Q3 2025 | 12 | $222.4M | KMTS, BBNX, BBOT, BCAX, NUVB |
| Q2 2025 | 13 | $154.4M | BBNX, KMTS, UPB, NUVB, BCAX |
| Q1 2025 | 13 | $169.5M | KMTS, BCAX, BBNX, NUVB, REPL |
| Q4 2024Amended | 12 | $154.2M | BCAX, NUVB, UPB, REPL, LXEO |
| Q3 2024 | 11 | $160.0M | BCAX, NUVB, REPL, LXEO, ENGN |
| Q2 2024 | 11 | $135.0M | NUVB, LXEO, REPL, ENGN, ALMS |
| Q1 2024 | 11 | $155.0M | NUVB, LXEO, REPL, ENGN, SANA |